A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:

A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05704049
• Other study ID #: ACT17453
• Secondary ID: U1111-1280-50902
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 5, 2023
• Est. completion date: March 1, 2027

Study information

• Verified date: May 2024
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery methods of SC isatuximab.

Description:

The duration of the study for a participant will include a period for screening of up to 28 days. A cycle duration is 28 days. Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue treatment, or any other reason, as well as the study treatment is commercially available and reimbursed in the participant's country, or is available from another source, whichever is first. The overall study duration will be of approximately 45 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 71
• Est. completion date: March 1, 2027
• Est. primary completion date: October 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants must have a documented diagnosis of multiple myeloma (MM)

• Participants with measurable disease defined as at least one of the following:

• Serum M-protein =0.5 g/dL measured using serum protein immunoelectrophoresis and/or

• Urine M-protein =200 mg/24 hours measured using urine protein immunoelectrophoresis and/or

• Serum free light chain (FLC) assay: Involved FLC assay =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).

• Participant with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy.

• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP) or agrees to practice complete abstinence or use approved contraception methods.

• Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy.

• Capable of giving signed informed consent.

Exclusion Criteria:

• Primary refractory MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course

• Participants with prior anti-CD38 treatment if: a) administered <9 months before first isatuximab administration or randomization as applicable or, b) Intolerant to the anti-CD38 previously received

• Prior treatment with carfilzomib

• Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or excipient) of study treatment that are not amenable to premedication with steroids, or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents

• Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis

• Any severe acute or chronic medical condition which could impair the ability of the participant to participate in the study or interfere with interpretation of study results (eg, systemic infection unless specific anti-infective therapy is employed) or participant unable to comply with the study procedures.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed/Refractory Multiple Myeloma

Intervention

Drug:
• Isatuximab
Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
• Carfilzomib
Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
• Dexamethasone
Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
• Dexamethasone IV
Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
• Montelukast
Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
• Acetaminophen
Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
• Diphenhydramine
Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
• Methylprednisolone
Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV

Locations

Country	Name	City	State
Australia	Investigational Site Number : 0360001	Fitzroy	Victoria
Australia	Investigational Site Number : 0360002	Wollongong	New South Wales
Brazil	Hospital Mae de Deus Site Number : 0760002	Porto Alegre	Rio Grande Do Sul
Brazil	Clínica São Germano Site Number : 0760003	Sao Paulo	São Paulo
Brazil	Hospital das Clinicas de Sao Paulo Site Number : 0760001	Sao Paulo	São Paulo
Czechia	Investigational Site Number : 2030002	Brno
Czechia	Investigational Site Number : 2030004	Olomouc
Czechia	Investigational Site Number : 2030003	Ostrava - Poruba
Czechia	Investigational Site Number : 2030001	Praha 2
Greece	Investigational Site Number : 3000001	Athens
Greece	Investigational Site Number : 3000002	Athens
Greece	Investigational Site Number : 3000003	Thessaloniki
Japan	Investigational Site Number : 3920001	Kashiwa-shi	Chiba
Japan	Investigational Site Number : 3920002	Okayama-shi	Okayama
Portugal	Investigational Site Number : 6200001	Braga
Portugal	Investigational Site Number : 6200004	Lisboa
Portugal	Investigational Site Number : 6200005	Lisboa

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

Australia,  Brazil,  Czechia,  Greece,  Japan,  Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR)	ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC).	6 months after the Last Participant In (LPI) i.e., approximately 16 months
Secondary	Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6	Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2).	6 months from LPI i.e., approximately 16 months
Secondary	Incidence rate of infusion reactions (IRs)		18 months after LPI i.e., approximately 28 months
Secondary	Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters		From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months
Secondary	Incidence rate of injection site reactions (ISRs)		18 months after LPI i.e., approximately 28 months
Secondary	PK concentration: trough plasma concentration (Ctrough)	Blood samples will be collected for measurement of isatuximab concentrations.	Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days)
Secondary	Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by IRC		18 months after LPI i.e., approximately 28 months
Secondary	Duration of response (DOR)	DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first.	18 months after LPI i.e., approximately 28 months
Secondary	Time to first response (TT1R)	TT1R defined as time from randomization to first IRC determined response (PR or better) that is subsequently confirmed.	18 months after LPI i.e., approximately 28 months
Secondary	Time to best response (TTBR)	TTBR defined as time from randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed.	18 months after LPI i.e., approximately 28 months
Secondary	Progression free survival (PFS)	PFS defined as time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever comes first.	18 months after LPI i.e., approximately 28 months
Secondary	Overall survival (OS)	OS defined as time from the date of randomization to death from any cause	18 months after LPI i.e., approximately 28 months
Secondary	Incidence of participants with anti-drug antibodies (ADA) against isatuximab		From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days)
Secondary	Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously	PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication).	Baseline
Secondary	Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously	PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method. This questionnaire has been developed using industry standard for instrument development and has been debriefed and adapted based on qualitative interviews with oncology patients. The more general treatment expectations instrument (v1) was further adapted and debriefed with patients to assess manual and OBDS subcutaneous delivery (v2). The PESQ v2 contains a total of 9 items. There are 6 items that are administered for the duration of treatment, and 3 preference items administered only after patient experience of both manual and OBDS.	18 months after LPI i.e., approximately 28 months
Secondary	Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ)	Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history.	18 months after LPI i.e., approximately 28 months
Secondary	Health Related Quality of Life (HRQL)	HRQL is assessed using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM.	18 months after LPI i.e., approximately 28 months
Secondary	European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)	Health status is assessed using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents.	18 months after LPI i.e., approximately 28 months